MX2022011730A - Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. - Google Patents
Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.Info
- Publication number
- MX2022011730A MX2022011730A MX2022011730A MX2022011730A MX2022011730A MX 2022011730 A MX2022011730 A MX 2022011730A MX 2022011730 A MX2022011730 A MX 2022011730A MX 2022011730 A MX2022011730 A MX 2022011730A MX 2022011730 A MX2022011730 A MX 2022011730A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antagonist
- atopic dermatitis
- administering
- treating atopic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001224P | 2020-03-27 | 2020-03-27 | |
| EP21315010 | 2021-01-28 | ||
| PCT/US2021/024419 WO2021195530A1 (en) | 2020-03-27 | 2021-03-26 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011730A true MX2022011730A (es) | 2022-10-13 |
Family
ID=75498103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011730A MX2022011730A (es) | 2020-03-27 | 2021-03-26 | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230102151A1 (https=) |
| EP (1) | EP4126951A1 (https=) |
| JP (1) | JP2023520676A (https=) |
| KR (1) | KR20220158821A (https=) |
| CN (1) | CN115427450A (https=) |
| AU (1) | AU2021244266A1 (https=) |
| BR (1) | BR112022015363A2 (https=) |
| CA (1) | CA3173173A1 (https=) |
| IL (1) | IL296214A (https=) |
| MX (1) | MX2022011730A (https=) |
| WO (1) | WO2021195530A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PT3889181T (pt) | 2012-09-07 | 2024-05-29 | Regeneron Pharma | Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| HUE067888T2 (hu) | 2016-09-01 | 2024-11-28 | Regeneron Pharma | Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| WO2021026205A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| IL310962A (en) | 2021-08-23 | 2024-04-01 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an IL-4R antagonist |
| US20230220089A1 (en) * | 2021-12-30 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| BRPI0416603A (pt) | 2003-11-07 | 2007-01-30 | Immunex Corp | anticorpo que se liga ao receptor interleucina-4 (il-4) humano |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| PT3889181T (pt) | 2012-09-07 | 2024-05-29 | Regeneron Pharma | Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração |
| AU2017220184B2 (en) * | 2016-02-19 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
-
2021
- 2021-03-26 MX MX2022011730A patent/MX2022011730A/es unknown
- 2021-03-26 EP EP21718786.3A patent/EP4126951A1/en active Pending
- 2021-03-26 US US17/907,070 patent/US20230102151A1/en not_active Abandoned
- 2021-03-26 BR BR112022015363A patent/BR112022015363A2/pt unknown
- 2021-03-26 JP JP2022558017A patent/JP2023520676A/ja active Pending
- 2021-03-26 IL IL296214A patent/IL296214A/en unknown
- 2021-03-26 KR KR1020227037517A patent/KR20220158821A/ko active Pending
- 2021-03-26 CN CN202180024611.8A patent/CN115427450A/zh active Pending
- 2021-03-26 CA CA3173173A patent/CA3173173A1/en active Pending
- 2021-03-26 WO PCT/US2021/024419 patent/WO2021195530A1/en not_active Ceased
- 2021-03-26 AU AU2021244266A patent/AU2021244266A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL296214A (en) | 2022-11-01 |
| BR112022015363A2 (pt) | 2022-09-20 |
| AU2021244266A1 (en) | 2022-12-01 |
| KR20220158821A (ko) | 2022-12-01 |
| CA3173173A1 (en) | 2021-09-30 |
| EP4126951A1 (en) | 2023-02-08 |
| WO2021195530A1 (en) | 2021-09-30 |
| JP2023520676A (ja) | 2023-05-18 |
| US20230102151A1 (en) | 2023-03-30 |
| CN115427450A (zh) | 2022-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011730A (es) | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| MX2024002072A (es) | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| MX2024010244A (es) | Uso de un inhibidor del receptor de interleucina-4 (il-4r) para tratar la dermatitis atopica. | |
| CL2025002241A1 (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
| MX2025005113A (es) | Metodos para tratar la dermatitis de manos y pies mediante la administracion de un antagonista de il-4r | |
| IL289930A (en) | Methods for treating atopic dermatitis using an IL-4R antagonist | |
| EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| AU2014306956B2 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| JO3559B1 (ar) | جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| MX2023014187A (es) | Un inhibidor de receptor de interleucina-4 para usarse en el tratamiento de la dermatitis atopica severa. | |
| AU2017228470A8 (en) | Combination therapy with anti-CD73 antibodies | |
| EP4649999A3 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| PH12013502201A1 (en) | Anti-b7-h3 antibody | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| MX2024001189A (es) | Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r. | |
| MX2021013427A (es) | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. | |
| EP4276108A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| MX2025011152A (es) | Metodos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc) mediante la administracion de un antagonista de il-4r | |
| MX2025011114A (es) | Metodos para el tratamiento de la gastroenteritis eosinofilica mediante la administracion de un antagonista de il-4r | |
| MX2024004762A (es) | Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r. | |
| MX2024006053A (es) | Metodos para atenuar la marcha atopica administrando un antagonista de il-4/il-13. | |
| NZ631118A (en) | Methods for treating nasal polyposis by administering an il-4r antagonist | |
| EA201691012A1 (ru) | Обходной канал предварительного риформинга |